Long-term persistence of anti-HAV antibodies following active immunization with hepatitis A vaccine

Maiwald, H.; Jilg, Wolfgang; Bock, H.L.; Löscher, Thomas; Sonnenburg, Frank von

doi:10.1016/s0264-410x(97)00211-9

Cited by 40 publications

(19 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Published data from different trials with different doses of different hepatitis A vaccines, however, all seem to match this observation [Van Damme et al, 1994b;Wiens et al, 1996;Maiwald et al, 1997;Totos et al, 1997;Wiedermann et al, 1997Wiedermann et al, , 1998Bovier et al, 1999;Van Herck et al, 2000]. During the first year after the last vaccine dose, the annual decline rate is >60% in all papers (including this one).…”

Section: Discussionsupporting

confidence: 60%

Inactivated hepatitis A vaccine-induced antibodies: Follow-up and estimates of long-term persistence

Herck

Damme

2000

J. Med. Virol.

View full text Add to dashboard Cite

To estimate the long-term persistence of anti-HAV antibodies, 120 (schedule 0-6) and 194 (schedule 0-12) adults were vaccinated and followed-up annually for 6 years. Shortly after the last dose, anti-HAV levels fell sharply (annual decline rate delta > 65%). Thereafter, delta diminished to 10-15%. GMTs 5.5 years after the last dose were 522 mIU/ml (0-6 group) and 749 mIU/ml (0-12 group); all subjects except one maintained detectable antibodies. The average delta over the whole follow-up period was 15-20%, resulting in an estimated persistence of anti-HAV levels > or =20 mIU/ml for 20-25 years. These estimates were similar for both applied calculation methods (GMT or individual based) and both vaccination schedules. Because the individual antibody levels tended to stabilise between the last two measurements, the hypothesis of a slow, log-linear decrease and its matching calculation methods might be subject to reconsideration. With the current methodology, however, detectable antibodies are estimated to persist for 20-25 years.

show abstract

Section: Discussionsupporting

confidence: 60%

Inactivated hepatitis A vaccine-induced antibodies: Follow-up and estimates of long-term persistence

Herck

Damme

2000

J. Med. Virol.

View full text Add to dashboard Cite

show abstract

“…These models predicted rates of decline for anti-HAV GMCs to persist above seroprotective levels for 15-32 years [4,5,[13][14][15][16]. However, we observed no statistically significant difference between anti-HAV GMCs recorded between 10 and 14 years in this two-dose vaccine regimen and we have reported that they are also not different between 10 and 17 years for the three-dose immunization schedule [6].…”

Section: Discussionmentioning

confidence: 49%

Duration of protection against hepatitis A for the current two-dose vaccine compared to a three-dose vaccine schedule in children

Raczniak

Thomas

Bulkow

et al. 2013

Vaccine

View full text Add to dashboard Cite

Background-Hepatitis A is mostly a self-limiting disease but causes substantial economic burden. Consequently, United States Advisory Committee for Immunization Practices recommends inactivated hepatitis A vaccination for all children beginning at age 1 year and for high risk adults. The hepatitis A vaccine is highly effective but the duration of protection is unknown.Methods-We examined the proportion of children with protective hepatitis A antibody levels (anti-HAV ≥20 mIU/mL) as well as the geometric mean concentration (GMC) of anti-HAV in a cross sectional convenience sample of individuals aged 12-24 years, who had been vaccinated with a two-dose schedule in childhood, with the initial dose at least 5 years ago. We compared a HHS Public Access Author Manuscript Author ManuscriptAuthor ManuscriptAuthor Manuscript subset of data from persons vaccinated with two-doses (720 EL.U.) at age 3-6 years with a demographically similar prospective cohort that received a three-dose (360 EL.U.) schedule and have been followed for 17 years.Results-No significant differences were observed when comparing GMC between the two cohorts at 10 (P = 0.467), 12 (P = 0.496), and 14 (P = 0.175) years post-immunization. For the three-dose cohort, protective antibody levels remain for 17 years and have leveled-off over the past 7 years. Conclusion-The two-and three-dose schedules provide similar protection >14 years after vaccination, indicating a booster dose is not needed at this time. Plateauing anti-HAV GMC levels suggest protective antibody levels may persist long-term.

show abstract

“…Seroconversion rates in children exceed ninety percent after an initial dose and approaches hundred percent after the second dose. 34 A study done in Chile showed that routine vaccination of toddlers reduced the rates of symptomatic hepatitis A and associated mortality. 33 The two-dose vaccine schedule evaluated in the study was less expensive than the disease related costs in the absence of vaccination from the sixth year of its implementation.…”

Section: Water First and Vaccinesmentioning

confidence: 99%

“…In Israel, Australia and Spain, routine childhood vaccination also resulted in marked reduction in the incidence of acute HAV infection. [34][35][36] The prospective duration of antibody persistence after vaccination is estimated to be at least 20 years. 23,37 Several HEV vaccines are under development, including a vaccine that has now completed a phase II randomized placebo-controlled trial in Nepal.…”

Section: Water First and Vaccinesmentioning

confidence: 99%

Faeco-orally transmitted viral hepatitis in african children

Ekanem¹,

Ikobah²,

Calabar³

et al. 2018

J Immunological Sci

View full text Add to dashboard Cite

1Department of paediatrics, university of calabar and university of calabar teaching hospital, calabar, nigeria. ABSTRACTThe faeco-orally transmitted hepatotropic viruses -hepatitis A and hepatitis E viruses-are endemic in Africa. While transmission has reduced remarkably in Europe and North America in the past decades, it has remained unchanged in Africa with hepatitis A prevalence remaining at above 50% and hepatitis E more than 7%. Much of this transmission occurs during childhood with the important drivers/predictors being poor water supply, poor sewage disposal facilities, low socioeconomic class, crowding, and poor social conditions arising from conflict. Initial clinical features in children are difficult to distinguish from malaria which is also endemic in the region. Commercially available ELISA kits present the best option for laboratory diagnosis of both viruses in Africa. While effective vaccines suitable for the African situation have been developed recently, improved water supply and sanitation are sine qua non for the prevention of transmission of both viruses among African children. Interventional studies are needed in the region.

show abstract

Long-term persistence of anti-HAV antibodies following active immunization with hepatitis A vaccine

Cited by 40 publications

References 5 publications

Inactivated hepatitis A vaccine-induced antibodies: Follow-up and estimates of long-term persistence

Inactivated hepatitis A vaccine-induced antibodies: Follow-up and estimates of long-term persistence

Duration of protection against hepatitis A for the current two-dose vaccine compared to a three-dose vaccine schedule in children

Faeco-orally transmitted viral hepatitis in african children

Contact Info

Product

Resources

About